Human equilibrative nucleoside transporter 1 (hENT1) expression is a potential predictive tool for response to gemcitabine in patients with advanced cholangiocarcinoma

European Journal of Cancer

Volumn 48, Issue 7, 2012, Pages 990-996

  Borbath, I ^a   Verbrugghe, L ^a   Lai, R ^b   Gigot, J F ^a   Humblet, Y ^a   Piessevaux, H ^a   Sempoux, C ^a  

^a CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^b UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Cholangiocarcinoma; Gemcitabine; hENT1

Indexed keywords

CARRIER PROTEIN; GEMCITABINE; HUMAN EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 1; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BILE DUCT CARCINOMA; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION COEFFICIENT; FEMALE; FOLLOW UP; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; PREDICTIVE VALIDITY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; BILE DUCT NEOPLASMS; CHOLANGIOCARCINOMA; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 1; FEMALE; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84859479209     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2011.11.006     Document Type: Article

References (23)

1. T. Patel Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States Hepatology 33 6 2001 1353 1357
2. A.M. Bouvier, L. Remontet, and E. Jougla Incidence of gastrointestinal cancers in France Gastroenterol Clin Biol 28 10 Pt 1 2004 877 881
3. P.C. de Groen, G.J. Gores, N.F. LaRusso, L.L. Gunderson, and D.M. Nagorney Biliary tract cancers N Engl J Med 341 18 1999 1368 1378
4. F. Eckel, and R.M. Schmid Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials Br J Cancer 96 6 2007 896 902
5. J. Valle, H. Wasan, and D.H. Palmer Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer N Engl J Med 362 14 2010 1273 1281
6. S. Marsh, and H.L. McLeod Cancer pharmacogenetics Br J Cancer 90 1 2004 8 11
7. R. Danesi, F. De Braud, S. Fogli, A. Di Paolo, and M. Del Tacca Pharmacogenetic determinants of anti-cancer drug activity and toxicity Trends Pharmacol Sci 22 8 2001 420 426
8. J.R. Mackey, S.A. Baldwin, J.D. Young, and C.E. Cass Nucleoside transport and its significance for anticancer drug resistance Drug Resist Update 1 5 1998 310 324
9. J. Garcia-Manteiga, M. Molina-Arcas, F.J. Casado, A. Mazo, and M. Pastor-Anglada Nucleoside transporter profiles in human pancreatic cancer cells: role of hCNT1 in 2′,2′-difluorodeoxycytidine-induced cytotoxicity Clin Cancer Res 9 13 2003 5000 5008
10. J.R. Mackey, S.Y. Yao, and K.M. Smith Gemcitabine transport in xenopus oocytes expressing recombinant plasma membrane mammalian nucleoside transporters J Natl Cancer Inst 91 21 1999 1876 1881
11. +- nucleoside cotransporter proteins (hCNT3 and mCNT3) broadly selective for purine and pyrimidine nucleosides (system cib) J Biol Chem 276 4 2001 2914 2927
12. Y. Nakano, S. Tanno, and K. Koizumi Gemcitabine chemoresistance and molecular markers associated with gemcitabine transport and metabolism in human pancreatic cancer cells Br J Cancer 96 3 2007 457 463
13. D. Santini, G. Perrone, and B. Vincenzi Human equilibrative nucleoside transporter 1 (hENT1) protein is associated with short survival in resected ampullary cancer Ann Oncol 19 4 2008 724 728
14. P. Seve, J.R. Mackey, and S. Isaac CN-II expression predicts survival in patients receiving gemcitabine for advanced non-small cell lung cancer Lung Cancer 49 3 2005 363 370
15. J.R. Mackey, L.L. Jennings, and M.L. Clarke Immunohistochemical variation of human equilibrative nucleoside transporter 1 protein in primary breast cancers Clin Cancer Res 8 1 2002 110 116
16. L. Chow, R. Lai, and L. Dabbagh Analysis of human equilibrative nucleoside transporter 1 (hENT1) protein in non-Hodgkin's lymphoma by immunohistochemistry Mod Pathol 18 4 2005 558 564
17. D. Santini, B. Vincenzi, and M.E. Fratto Prognostic role of human equilibrative transporter 1 (hENT1) in patients with resected gastric cancer J Cell Physiol 223 2 2011 384 388
18. J.J. Farrell, H. Elsaleh, and M. Garcia Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer Gastroenterology 136 1 2009 187 195
19. R. Marechal, J.R. Mackey, and R. Lai Human equilibrative nucleoside transporter 1 and human concentrative nucleoside transporter 3 predict survival after adjuvant gemcitabine therapy in resected pancreatic adenocarcinoma Clin Cancer Res 15 8 2009 2913 2919
20. A.F. Hezel, V. Deshpande, and A.X. Zhu Genetics of biliary tract cancers and emerging targeted therapies J Clin Oncol 28 21 2010 3531 3540
21. J. Spratlin, R. Sangha, and D. Glubrecht The absence of human equilibrative nucleoside transporter 1 is associated with reduced survival in patients with gemcitabine-treated pancreas adenocarcinoma Clin Cancer Res 10 20 2004 6956 6961
22. D. Santini, G. Schiavon, and B. Vincenzi Human equilibrative nucleoside transporter 1 (hENT1) levels predict response to gemcitabine in patients with Biliary Tract Cancer (BTC) Curr Cancer Drug Targets 11 1 2011 123 129
23. M. Molina-Arcas, G. Moreno-Bueno, and P. Cano-Soldado Human equilibrative nucleoside transporter-1 (hENT1) is required for the transcriptomic response of the nucleoside-derived drug 5'-DFUR in breast cancer MCF7 cells Biochem Pharmacol 72 12 2006 1646 1656